{"id":"c344da29b5d5","type":"article","url":"https://hartvaat.nl/2016/12/21/alirocumab-bij-heterozygoot-fh-met-lipoproteine-aferese-odyssey-escape/","title":"Alirocumab bij heterozygoot FH met lipoproteïne-aferese: ODYSSEY ESCAPE","title_en":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","lipide-aferese"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehw388","source_url":"https://doi.org/10.1093/eurheartj/ehw388","authors":["Patrick M Moriarty","Klaus G Parhofer","Stephan P Babirak","Marc-Andre Cornier","P Barton Duell","Bernd Hohenstein","Josef Leebmann","Wolfgang Ramlow","Volker Schettler","Vinaya Simha","Elisabeth Steinhagen-Thiessen","Paul D Thompson","Anja Vogt","Berndt von Stritzky","Yunling Du","Garen Manvelian"],"significance":7,"published":"2016-12-21","source_date":"2016-12-21","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"The ODYSSEY ESCAPE trial showed that alirocumab reduced the frequency of lipoprotein apheresis treatments by 75% in patients with heterozygous FH, demonstrating a pharmaceutical alternative to this burdensome procedure.","created":"2026-07-03T10:26:28Z","updated":"2026-07-03T13:25:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gerandomiseerde ODYSSEY ESCAPE-trial die alirocumab onderzocht bij patiënten met heterozygote familiaire hypercholesterolemie die lipoproteïne-aferese ondergaan. Toonde reductie in aferese-frequentie.","abstract_original":"AIM: To evaluate the effect of alirocumab on frequency of standard apheresis treatments [weekly or every 2 weeks (Q2W)] in heterozygous familial hypercholesterolaemia (HeFH). METHODS AND RESULTS: ODYSSEY ESCAPE (NCT02326220) was a double-blind study in 62 HeFH patients undergoing regular weekly or Q2W lipoprotein apheresis. Patients were randomly assigned (2:1, respectively) to receive alirocumab 150 mg (n = 41) or placebo (n = 21) Q2W subcutaneously for 18 weeks. From day 1 to week 6, apheresis rate was fixed according to the patient's established schedule; from weeks 7 to 18, apheresis rate was adjusted based on the patient's low-density lipoprotein cholesterol (LDL-C) response in a blinded fashion. Apheresis was not performed when the LDL-C value was ≥30% lower than the baseline (pre-apheresis) value. The primary efficacy endpoint was the rate of apheresis treatments over 12 weeks (weeks 7-18), standardized to number of planned treatments. In the alirocumab group the least square (LS) mean ± SE (95% confidence interval [CI]) per cent change in pre-apheresis LDL-C from baseline at week 6 was -53.7 ± 2.3 (-58.2 to - 49.2) compared with 1.6 ± 3.1 (-4.7 to 7.9) in the placebo group. The primary efficacy endpoint showed statistically significant benefit in favour of alirocumab (Hodges-Lehmann median estimate of treatment difference: 0.75; 95% CI 0.67-0.83; P < 0.0001). Therefore, alirocumab-treated patients had a 0.75 (75%) additional reduction in the standardized rate of apheresis treatments vs. placebo-treated patients. During this period, 63.4% of patients on alirocumab avoided all and 92.7% avoided at least half of the apheresis treatments. Adverse event rates were similar (75.6% of patients on alirocumab vs. 76.2% on placebo). CONCLUSIONS: Lipoprotein apheresis was discontinued in 63.4% of patients on alirocumab who were previously undergoing regular apheresis, and the rate was at least halved in 92.7% of patients. Alirocumab was generally safe and well tolerated."}